The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration
Open accessPublished version of a preprint
Abstract
Antisense oligonucleotides (ASOs) have emerged as a new class of drugs to treat a wide range of diseases, including neurological indications. Spinraza, an ASO that modulates splicing of SMN2 RNA, has shown profound disease modifying effects in Spinal Muscular Atrophy (SMA) patients, energizing efforts to develop ASOs for other neurological diseases. While SMA specifically affects spinal motor neurons, other neurological diseases affect different central nervous system (CNS) regions, neuronal and non-neuronal cells. Therefore, it is important to characterize ASO distribution and activity in all major CNS structures and cell types to have a better understanding of which neurological diseases are amenable to ASO therapy. Here we present for the first time the atlas of ASO distribution and activity in the CNS of mice, rats, and non-human primates (NHP), species commonly used in preclinical therapeutic development. Following central administration of an ASO to rodents, we observe widespread distribution and target RNA reduction throughout the CNS in neurons, oligodendrocytes, astrocytes and microglia. This is also the case in NHP, despite a larger CNS volume and more complex neuroarchitecture. Our results demonstrate that ASO drugs are well suited for treating a wide range of neurological diseases for which no effective treatments are available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“numerous studies suggest that ASOs are not well suited for deep brain structure targets [16,47,52].”
From Elucidating brain transport pathways and cell type-dependent gene silencing of a durable lipid–siRNA conjugate administered into cerebrospinal fluid (2025) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337
New tools for studying microglia in the mouse and human CNS
Bennett, M. L., Bennett, F. C., Liddelow, S. A., Ajami, B., Zamanian, J. L., Fernhoff, N. B., Mulinyawe, S. B., Bohlen, C. J., Adil, A., Tucker, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525528113 · Cited by 1,804
Bennett, C. F., & Swayze, E. E. (2010) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,431
Self-citationFrom charcot to lou gehrig: deciphering selective motor neuron death in als
Cleveland, D. W., & Rothstein, J. D. (2001) · Nature reviews. Neuroscience · doi:10.1038/35097565 · Cited by 1,389
Finkel, R. S., Chiriboga, C. A., Vajsar, J., Day, J., Montes, J., Vivo, D. C. D., Yamashita, M., Rigo, F., Hung, G., Schneider, E., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31408-8 · Cited by 1,039
Self-citationCrooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770
Self-citationTargeting Huntingtin Expression in Patients with Huntington’s Disease
Tabrizi, S. J., Leavitt, B. R., Landwehrmeyer, G. B., Wild, E. J., Saft, C., Barker, R. A., Blair, N. F., Craufurd, D., Priller, J., Rickards, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900907 · Cited by 708
Self-citationAntisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse modelPreprint
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 680
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–127 of 127
Korff, A., Yang, X., Ozdemir, O., Samanta, A., Wang, Y., Patni, T., Lavado, A., Kavirayani, A. M., Ochaba, J., Powers, B. E., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adx3491 · Cited by 2
Self-citationRNA Therapeutics Targeting Skeletal Muscle: Emerging Antisense and Gene-Modifying Strategies
Kuroda, T., & Yokota, T. (2026) · Biomolecules · doi:10.3390/biom16060794 · Cited by 1
Jiang, M., Cao, Q., Fang, H., & Tian, H. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115173 · Cited by 2
Editorial: Nucleic Acids Research virtual issue dedicated to nucleic acid therapeutics, 2018–2023
Belgrad, J., Fakih, H. H., Johnson, K. C., & Corey, D. R. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad1148 · Cited by 1
Jacquot, G., David, M., Pecqueux, B., Mechioukhi, Y., Girard, S. D., Godard, M., Varini, K., Boursery, C., FRAPOLLI, C., Sebastien, R. O. U. X., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.20.726486 · Cited by 1
Nucleic Acid Pharmaceutical Agents
Kohnken, R. A., Harbison, C. E., Klein, S., & Engelhardt, J. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821047-5.00017-8
Antisense Oligonucleotide Therapy Against SCA3
McLoughlin, H. S. (2023) · Contemporary clinical neuroscience · doi:10.1007/978-3-031-24345-5_16
New Therapeutic Chemical Modalities: Compositions, Modes-of-action, and Drug Discovery
Valeur, E. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00911
Antisense oligonucleotide drugs for neurological and neuromuscular diseases
Lane, R. M., & Bennett, C. F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00039-x
Malange, K. F., Lemes, J. B. P., Noble, B., Anchondo, Y., Morado-Urbina, C. E., Jadhav, S., Dochnal, S. A., Kambalimath, C., Álvarez, P., Fitzsimmons, B., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.19.654680
Self-citationMyers, L. S., Griffin, J. F., Christian, S., & Dindot, S. V. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.21.683566
Casals-Sendra, G., Jarne-Sanz, I., Catasús, N., Boluda-Luis, I., Quer, A., Amilibia, E., Lázaro, C., Serra, E., Blanco, I., & Castellanos, E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.14.688164
Improved Efficacy and Tolerability of Antisense Oligonucleotide with Guanidine-Bridged Nucleic Acid
Kawanobe, T., Shrestha, A. R., & Tomita, H. (2026) · Nucleic Acid Therapeutics · doi:10.64898/2026.01.08.698310
Guise, A. J., Sellon, M. T., Roemer, S. F., Monine, M. I., Comfort, N. T., Bartlett, D., David, E., Xu, S., Jandreski, L., Malek, S., et al. (2026) · JAMA Neurology · doi:10.1001/jamaneurol.2026.2195
Myers, L. S., Griffin, J. F., Christian, S., & Dindot, S. V. (2026) · Frontiers in Veterinary Science · doi:10.3389/fvets.2026.1861994
Hawley, Z. C. E., Guise, A. J., Pardo, I. D. R., Chowdhury, T., Hana, S., Zavodszky, M. I., Engle, L., Wiltberger, K., Bartlett, D., Raitcheva, D., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201818
Casals-Sendra, G., Jarne-Sanz, I., Catasús, N., Boluda-Luis, I., Quer, A., Amilibia, E., Plotkin, S. R., Lázaro, C., Serra, E., Blanco, I., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103046
Safety and toxicity assessment of antisense oligonucleotides in brain-relevant human cellular models
Zanjko, L. C., Andrés-Santamaria, R., Balogh, A., van Roon-Mom, W. M. C., & Dinnyés, A. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103062
Astrocytes in Neurodegeneration: Spatial States, Crosstalk, and Emerging Therapies
Steger, L., Rothhammer, V., & Zunke, F. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06142-x
Naki, M., Kattan, F.-G., Pantazopoulou, M., Skea, S., Zisis, D., Pilalis, E., Fouka, M., Koronaiou, E., Fotis, C., Rieß, O., et al. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00577-x
Systemic and local delivery of siRNA to the CNS and periphery via anti-IGF1R antibody conjugation
Tian, M., Nikan, M., Yoo, M., Klein, S. K., Kwon, S., Matson, J. E., Kim, D., Jung, J., Hyeon, S., Yoo, B. M., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103105
Self-citationAntisense Oligonucleotides that Are Toxic to Prion-Infected Mice Share an Emergent Mechanism
Zhao, H. T., O’Moore, J., Sprague, D. A., Gentile, J. E., Damle, S. S., Noble, B., Corridon, T. L., Lord, S., Le, J., Graffam, S., et al. (2026) · Nucleic Acid Therapeutics · doi:10.1177/21593337261494829
Self-citationNovel Technologies and Clinical Breakthroughs: The Evolving Landscape of Gene Therapy in China
Li, J., Deng, Y., Ma, J., Huang, M., & Deng, H. (2026) · Human Gene Therapy · doi:10.1177/10430342261498531
Malange, K., Lemes, J. B. P., Noble, B., Anchondo, Y., Morado-Urbina, C. E., Jadhav, S., Yadav, S., Ma, J., Augustine, V., Dochnal, S. A., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.196154
Self-citationRöttgering, B., Weij, R., Bijl, S., Verheul, R. C., Testerink, J., Toonen, L. J. A., Bragg, R. M., Carroll, J. B., Beekman, C., & Datson, N. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.16.758452
Prevention of prion disease symptoms in mice with deep PrP loweringPreprint
Gentile, J. E., Farley, J. E., Kelemen, M. N., Mortberg, M. A., Corridon, T. L., Laversenne, V., Bombardier, J. R., Umaña, C., DeSouza-Lenz, K., Howard, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.22.761034
Metadata
- Authors
- Jafar-nejad, P., Powers, B., Soriano, A., Zhao, H., Norris, D. A., Matson, J., DeBrosse-Serra, B., Watson, J., Narayanan, P., Chun, S. J., Mazur, C., Kordasiewicz, H., Swayze, E. E., & Rigo, F.
- Affiliations
- Ionis Pharmaceuticals Inc. Carlsbad, CA 92010, USA
- Ionis Pharmaceuticals (United States) (US)
- Corresponding author
- Rigo, Frank
- ORCID
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-12-24
- Volume
- 49
- Issue
- 2
- Pages
- 657-673
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC7826274
- OpenAlex
- W3114205754
- Cited by
- 128
- References
- 56
- Citations by year
- 2026: 32 · 2025: 23 · 2024: 24 · 2023: 21 · 2022: 22 · 2021: 5 · 2020: 1
- FWCI
- 3.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- antisense oligonucleotides, RNase H, central nervous system distribution, spinal muscular atrophy, SMN2 splicing, oligodendrocytes, astrocytes, microglia, neurons, non-human primates, rodents, centralized management, neurological disease therapy
- MeSH terms
- Animals, Central Nervous System, Female, Injections, Intraventricular, Injections, Spinal, Macaca fascicularis, Male, Neuroglia, Neurons, Organ Specificity, Primates, Tissue Distribution, Oligonucleotides, Antisense, Ribonuclease H, Rats, Sprague-Dawley, In Situ Hybridization, Mice, Rats, RNA, Long Noncoding
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
